Europe’s premier life science legal strategy forum is back for its largest, most ambitious edition to date in Frankfurt this 13th-14th October 2026.

Delivering you tailored, interdisciplinary legal content, this refreshed event delves into practical and lived experiences of practitioners discussing the overall life science strategy sector, IP, regulatory, competition and corporate law. Get ready for nuanced debate, actionable takeaways and senior networking opportunities, which will help you sharpen your legal strategy and establish key contacts tailored to your work.

2026 Featured Speakers Include


450+
Attendees
60+
Speakers
10+
Hours of Dedicated Networking
50%
In-House Counsel

Discussion topics to look forward to at
LSLS 2026
will include 

Holistic Keynote Discussions

Learn how the industry is responding to cross-practice challenges, from EU legislative reform and intensifying geopolitical pressure to rising antitrust scrutiny, with insights from General Counsel, senior policymakers, private practice experts and more.

IP & Exclusivity Strategy

Receive high-level, actionable insights from Europe, the U.S., Brazil, China and beyond on the most pressing challenges shaping patent protection and exclusivity, from SPCs and second medical use claims to antibody patenting and AI-assisted inventions.

Policy, Market Access & Regulatory Strategy

Understand how the EU Pharma Package, Most Favoured Nation (MFN) pricing, the EU Biotech Act and more are reshaping strategy at the intersection of life science legal policy and practice, and receive guidance on leveraging new regulatory pathways to your advantage.

Competition Law & Antitrust

Discover how antitrust risk is crystallising across practice areas right now through dedicated sessions on European Commission enforcement priorities, merger control, divisional practice, disparagement and more.

Corporate & Transactional Strategy

Explore how to execute transactions that withstand scrutiny and protect value, through dedicated sessions on cross-border M&A, merger control, portfolio transitions, foreign investment screening, post-deal integration risk and transaction strategy for life science SMEs.

Our Audience

LSLS 2026 brings together the life science legal elite, uniting private practices, regulatory affairs leaders, patent attorneys, competition specialists, and corporate law experts with senior in-house counsel from pharma and biotech originator, generic and biosimilar companies. With a balanced lineup of over 60 speakers representing multiple jurisdictions and industry perspectives, LSLS is the definitive meeting point to reflect on and sharpen your holistic life science legal strategy.

Whether you're struggling with IP strategy in the UPC era, navigating complex regulatory changes, adapting to new levels of competition scrutiny or handling IP- and competition-sensitive M&A agreements, this summit will deliver cutting-edge insights and actionable take-home messages relevant to your day-to-day work.

50%
In-House Counsel
35%
Law Firms & Specialist Consultants
10%
Service Providers
5%
Regulators, Authorities & Industry Bodies

Who You’ll Meet

The summit brings together the full spectrum of life science legal stakeholders, creating a uniquely multi-perspective and commercially focused forum for strategic discussion. 

Who
Who

Life Sciences

Who You’ll Meet - MOBILE VIEW ONLY

Who
Who

2026 Attendees Include



Bianca-Lucia Vos
“The presentations and panel discussions are such that they bring you up to speed in the shortest possible time and at the highest level. Combined with the opportunity to exchange ideas with colleagues, clients, and representatives of various offices in a pleasant atmosphere, this seminar is a highlight for me every year. ”
Bianca-Lucia Vos
Partner |  Hoffmann Eitle
James Horgan
“The conference has a wide range of speakers on engaging panels covering all an IP professional needs to know about hot topics in European case law and legislation.”
James Horgan
Chief IP Counsel, International Litigation & Policy |  MSD
Robin Elis

"Another great event.  The place to be if you want to get the latest developments on all things Life Science!"

Robin Elis
Partner |  Reddie & Grose LLP
Marcell Komlosi
“This was an excellent event to meet private practice and in-house IP professionals working in the life sciences sector. The speakers delivered high quality presentations, and the networking discussions were engaging. I definitely recommend this conference to attendees who would like to keep up to date with the latest developments in the IP and regulatory law in relation to life sciences. ”
Marcell Komlosi
Patent Counsel |  Debiopharm International SA
Michael Pears
“An outstanding conference for anyone navigating IP and regulatory exclusivity in the life science section.  Highly valuable to legal professionals working both in-house and in private practice, and for originator and generics companies.”
Michael Pears
Partner |  Potter Clarkson
Fleur Herrenschmidt
“Great Variety of topics and useful sharing of insights. Really good quality overall and good networking opportunities.”
Fleur Herrenschmidt
Chief Legal Officer |  Norgine
Axel Korth
"A perfect platform to exchange perspective and connect with colleagues across the industry facing similar challenges as oneself"
Axel Korth
Head Legal DACH/UK&I/Nordics & CEE |  Biocon
Eva Ehlich
"The event is unique in Europe in bringing together a great number of practitioners from in-house and external as well as from institutions to discuss the most important topics for the pharma industry."
Eva Ehlich
Partner |  Maiwald

Our 2026 Partners

Photo Gallery

Loading